D2 receptor genetic variation and clinical response to antipsychotic drug treatment: a meta-analysis
- PMID: 20194480
- PMCID: PMC2896457
- DOI: 10.1176/appi.ajp.2009.09040598
D2 receptor genetic variation and clinical response to antipsychotic drug treatment: a meta-analysis
Abstract
Objective: Several lines of evidence suggest that antipsychotic drug efficacy is mediated by dopamine type 2 (D(2)) receptor blockade. Therefore, it seems plausible that variation in the DRD(2) gene is associated with clinical response to antipsychotic drug treatment. The authors conducted the first meta-analysis to examine the relationship between DRD2 polymorphisms and antipsychotic drug response.
Method: A MEDLINE search of articles available up to December 31, 2008, yielded 18 prospective studies examining DRD2 gene variation and antipsychotic response in schizophrenia patients; of which, 10 independent studies met criteria for inclusion. Clinical response to antipsychotic treatment was defined as a 50% reduction of either the Brief Psychiatric Rating Scale total score or Positive and Negative Syndrome Scale total score at approximately 8 weeks of follow-up evaluation. Odds ratio was the primary effect-size measure and computed for each polymorphism in each study. Sufficient data were available for two DRD2 polymorphisms: -141C Ins/Del and Taq1A.
Results: Six studies reported results for the -141C Ins/Del polymorphism (total sample size: N=687). The Del allele carrier was significantly associated with poorer antipsychotic drug response relative to the Ins/Ins genotype. Eight studies assessed the Taq1A polymorphism and antipsychotic response (total sample size: N=748). There was no significant difference in the response rate among A1 allele carriers relative to individuals with the A2/A2 genotype or A2 allele carriers relative to individuals with the A1/A1 genotype.
Conclusions: The DRD2 genetic variation is associated with clinical response to antipsychotic drug treatment. These data may provide proof-of-principle for pharmacogenetic studies in schizophrenia.
Conflict of interest statement
Figures





Similar articles
-
Variants in the DRD2 locus and antipsychotic-related prolactin levels: A meta-analysis.Psychoneuroendocrinology. 2016 Oct;72:1-10. doi: 10.1016/j.psyneuen.2016.06.002. Epub 2016 Jun 6. Psychoneuroendocrinology. 2016. PMID: 27333159 Free PMC article. Review.
-
Sexual dysfunction in male schizophrenia: influence of antipsychotic drugs, prolactin and polymorphisms of the dopamine D2 receptor genes.Pharmacogenomics. 2011 Aug;12(8):1127-36. doi: 10.2217/pgs.11.46. Epub 2011 Jul 12. Pharmacogenomics. 2011. PMID: 21749219
-
The -141C Ins/Del polymorphism in the dopamine D2 receptor gene promoter region is associated with anxiolytic and antidepressive effects during treatment with dopamine antagonists in schizophrenic patients.Pharmacogenetics. 2001 Aug;11(6):545-50. doi: 10.1097/00008571-200108000-00009. Pharmacogenetics. 2001. PMID: 11505224
-
The -141C Ins/Del and Taq1A polymorphism in the dopamine D2 receptor gene may confer susceptibility to schizophrenia in Asian populations.J Clin Neurosci. 2016 Aug;30:1-7. doi: 10.1016/j.jocn.2015.10.052. Epub 2016 Jun 6. J Clin Neurosci. 2016. PMID: 27283386 Review.
-
Dopamine (DRD2) and Serotonin (HTR2A, 2C) Receptor Gene Polymorphisms do not influence early response to Risperidone in South Indian Patients with Schizophrenia.Fundam Clin Pharmacol. 2019 Jun;33(3):355-364. doi: 10.1111/fcp.12424. Epub 2018 Nov 21. Fundam Clin Pharmacol. 2019. PMID: 30332506
Cited by
-
Genetics in child and adolescent psychiatry: methodological advances and conceptual issues.Eur Child Adolesc Psychiatry. 2015 Jun;24(6):619-34. doi: 10.1007/s00787-015-0702-8. Epub 2015 Apr 8. Eur Child Adolesc Psychiatry. 2015. PMID: 25850999 Review.
-
Personalized medicine in psychiatry: problems and promises.BMC Med. 2013 May 16;11:132. doi: 10.1186/1741-7015-11-132. BMC Med. 2013. PMID: 23680237 Free PMC article. Review.
-
The Gut Microbiome and Treatment-Resistance in Schizophrenia.Psychiatr Q. 2020 Mar;91(1):127-136. doi: 10.1007/s11126-019-09695-4. Psychiatr Q. 2020. PMID: 31781943 Review.
-
Towards the clinical implementation of pharmacogenetics in bipolar disorder.BMC Med. 2014 May 30;12:90. doi: 10.1186/1741-7015-12-90. BMC Med. 2014. PMID: 24885933 Free PMC article.
-
Scientific challenges and implementation barriers to translation of pharmacogenomics in clinical practice.ISRN Pharmacol. 2013;2013:641089. doi: 10.1155/2013/641089. Epub 2013 Feb 28. ISRN Pharmacol. 2013. PMID: 23533802 Free PMC article.
References
-
- Kane JM. Pharmacologic treatment of schizophrenia. Biol Psychiatry. 1999;46(10):1396–408. - PubMed
-
- Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Keefe RS, Davis SM, Davis CE, Lebowitz BD, Severe J, Hsiao JK. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005;353(12):1209–23. - PubMed
-
- Jones PB, Barnes TR, Davies L, Dunn G, Lloyd H, Hayhurst KP, Murray RM, Markwick A, Lewis SW. Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1) Arch Gen Psychiatry. 2006;63(10):1079–87. - PubMed
-
- Kahn RS, Fleischhacker WW, Boter H, Davidson M, Vergouwe Y, Keet IP, Gheorghe MD, Rybakowski JK, Galderisi S, Libiger J, Hummer M, Dollfus S, Lopez-Ibor JJ, Hranov LG, Gaebel W, Peuskens J, Lindefors N, Riecher-Rossler A, Grobbee DE. Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet. 2008;371(9618):1085–97. - PubMed
-
- Malhotra AK, Murphy GM, Jr, Kennedy JL. Pharmacogenetics of psychotropic drug response. Am J Psychiatry. 2004;161(5):780–96. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases
Miscellaneous